122 related articles for article (PubMed ID: 9754940)
1. Characterisation of new efaroxan derivatives for use in purification of imidazoline-binding sites.
Chan SL; Pallett AL; Clews J; Ramsden CA; Chapman JC; Kane C; Dunne MJ; Morgan NG
Eur J Pharmacol; 1998 Aug; 355(1):67-76. PubMed ID: 9754940
[TBL] [Abstract][Full Text] [Related]
2. Effects of the imidazoline ligands efaroxan and KU14R on blood glucose homeostasis in the mouse.
Mayer G; Taberner PV
Eur J Pharmacol; 2002 Nov; 454(1):95-102. PubMed ID: 12409010
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX801080.
Brown CA; Chan SL; Stillings MR; Smith SA; Morgan NG
Br J Pharmacol; 1993 Nov; 110(3):1017-22. PubMed ID: 7905338
[TBL] [Abstract][Full Text] [Related]
4. Essential role of the imidazoline moiety in the insulinotropic effect but not the KATP channel-blocking effect of imidazolines; a comparison of the effects of efaroxan and its imidazole analogue, KU14R.
Bleck C; Wienbergen A; Rustenbeck I
Diabetologia; 2005 Dec; 48(12):2567-75. PubMed ID: 16283242
[TBL] [Abstract][Full Text] [Related]
5. Evidence that the ability of imidazoline compounds to stimulate insulin secretion is not due to interaction with sigma receptors.
Chan SL; Pallett AL; Clews J; Ramsden CA; Morgan NG
Eur J Pharmacol; 1997 Apr; 323(2-3):241-4. PubMed ID: 9128845
[TBL] [Abstract][Full Text] [Related]
6. ATP-sensitive potassium channels and efaroxan-induced insulin release in the electrofusion-derived BRIN-BD11 beta-cell line.
Chapman JC; McClenaghan NH; Cosgrove KE; Hashmi MN; Shepherd RM; Giesberts AN; White SJ; Ammälä C; Flatt PR; Dunne MJ
Diabetes; 1999 Dec; 48(12):2349-57. PubMed ID: 10580423
[TBL] [Abstract][Full Text] [Related]
7. Clotrimazole and efaroxan stimulate insulin secretion by different mechanisms in rat pancreatic islets.
Chan SL; Pallett AL; Morgan NG
Naunyn Schmiedebergs Arch Pharmacol; 1997 Dec; 356(6):763-8. PubMed ID: 9453462
[TBL] [Abstract][Full Text] [Related]
8. Interactions between imidazoline compounds and sulphonylureas in the regulation of insulin secretion.
Mourtada M; Brown CA; Smith SA; Piercy V; Chan SL; Morgan NG
Br J Pharmacol; 1997 Jun; 121(4):799-805. PubMed ID: 9208151
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan.
Chan SL; Mourtada M; Morgan NG
Diabetes; 2001 Feb; 50(2):340-7. PubMed ID: 11272145
[TBL] [Abstract][Full Text] [Related]
10. Imidazoline/guanidinium binding sites and their relation to inhibition of K(ATP) channels in pancreatic B-cells.
Rustenbeck I; Herrmann C; Ratzka P; Hasselblatt A
Naunyn Schmiedebergs Arch Pharmacol; 1997 Sep; 356(3):410-7. PubMed ID: 9303581
[TBL] [Abstract][Full Text] [Related]
11. Affinity isolation of imidazoline binding proteins from rat brain using 5-amino-efaroxan as a ligand.
Monks LK; Cosgrove KE; Dunne MJ; Ramsden CA; Morgan NG; Chan SL
FEBS Lett; 1999 Mar; 447(1):61-4. PubMed ID: 10218583
[TBL] [Abstract][Full Text] [Related]
12. Evidence for two different imidazoline sites on pancreatic B cells and vascular bed in rat.
Berdeu D; Gross R; Puech R; Loubatières-Mariani MM; Bertrand G
Eur J Pharmacol; 1995 Feb; 275(1):91-8. PubMed ID: 7774667
[TBL] [Abstract][Full Text] [Related]
13. The imidazoline I1 receptor agonist, moxonidine, inhibits insulin secretion from isolated rat islets of Langerhans.
Tsoli E; Chan SL; Morgan NG
Eur J Pharmacol; 1995 Sep; 284(1-2):199-203. PubMed ID: 8549627
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of locus coeruleus neurons by non-I1/I2-type imidazoline receptors: an in vivo and in vitro electrophysiological study.
Ugedo L; Pineda J; Ruiz-Ortega JA; Martín-Ruiz R
Br J Pharmacol; 1998 Dec; 125(8):1685-94. PubMed ID: 9886760
[TBL] [Abstract][Full Text] [Related]
15. The effect of the putative endogenous imidazoline receptor ligand, clonidine-displacing substance, on insulin secretion from rat and human islets of Langerhans.
Chan SL; Atlas D; James RF; Morgan NG
Br J Pharmacol; 1997 Mar; 120(5):926-32. PubMed ID: 9138700
[TBL] [Abstract][Full Text] [Related]
16. The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I1- and I2-sites.
Chan SL; Brown CA; Scarpello KE; Morgan NG
Br J Pharmacol; 1994 Aug; 112(4):1065-70. PubMed ID: 7952865
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of insulin secretion by the imidazoline alpha 2-adrenoceptor antagonist efaroxan is mediated by a novel, stereoselective, binding site.
Chan SL; Brown CA; Morgan NG
Eur J Pharmacol; 1993 Jan; 230(3):375-8. PubMed ID: 8095024
[TBL] [Abstract][Full Text] [Related]
18. Effector systems involved in the insulin secretory responses to efaroxan and RX871024 in rat islets of Langerhans.
Mourtada M; Smith SA; Morgan NG
Eur J Pharmacol; 1998 Jun; 350(2-3):251-8. PubMed ID: 9696415
[TBL] [Abstract][Full Text] [Related]
19. Agmatine is not a good candidate as endogenous ligand for imidazoline sites of pancreatic B cells and vascular bed.
Berdeu D; Puech R; Loubatières-Mariani MM; Bertrand G
Eur J Pharmacol; 1996 Jul; 308(3):301-4. PubMed ID: 8858303
[TBL] [Abstract][Full Text] [Related]
20. Insulin secretagogues with an imidazoline structure inhibit arginine-induced secretion from isolated glucagon secretion from isolated rat islets of Langerhans.
Mourtada M; Smith SA; Morgan NG
Biochem Biophys Res Commun; 1997 Jul; 236(1):162-6. PubMed ID: 9223445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
